Consequently, targeting both CEACAM1 and TIM-3 concurrently holds promise as a strategy to enhance anti-tumor immune responses in CRC, as evidenced by successful outcomes in CRC mouse models (151). This evidence concerns the gene HAVCR2 and colorectal carcinoma.